400 Professional Drive
About Emergent BioSolutions
Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through our specialty products and contract development and manufacturing services, we are dedicated to providing solutions that address public health threats. Through social responsibility, we aim to build healthier and safer communities. We aspire to deliver peace of mind to our patients and customers so they can focus on what’s most important in their lives. In working together, we envision protecting or enhancing 1 billion lives by 2030. For more information visit www.emergentbiosolutions.com. Find us on LinkedIn and follow us on Twitter.
Stock Symbol: EBS
491 articles with Emergent BioSolutions
Biotech Bay, the bustling biotech industry around San Francisco in California, is home to many biopharma companies developing diagnostics, therapies, and vaccines to fight against coronavirus disease 2019 (COVID-19) and the virus that causes it, called SARS-CoV-2.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 20, 2020.
- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the following virtual investor conferences this month: BofA Securities 2020 Virtual Health Care Conference May 12-13 (presentation on May 12) Evercore ISI Vaccine Investor Day 2020 May 19 (no webcast presentation; virtual meetings only) 2020 6 th Annual SunTrust Robinson Humphrey Life Sciences Virt
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 21, 2020 at 9:00am EDT
Emergent BioSolutions Inc. (NYSE: EBS) announced today that its 2020 Annual Meeting of Stockholders will be held in a virtual-only format via live audio webcast on Thursday, May 21, 2020 at 9:00 AM EDT. The Company, which disclosed the move to virtual-only format in all proxy materials related to the 2020 Annual Meeting of Stockholders, has taken this step to support the health and well-being of meeting participants in light of the COVID-19 p
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 5, 2020.
Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the three months ended March 31, 2020.
Less than one month after Johnson & Johnson identified a lead vaccine candidate against COVID-19, the life sciences giant announced an agreement with Emergent BioSolutions to support the manufacturing needs for the potential medication.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 24, 2020.
Johnson & Johnson Announces Collaboration to Expand Manufacturing Capabilities For its COVID-19 Vaccine Candidate in Support of the Company's Goal to Supply More Than One Billion Vaccine Doses Globally
First in Series of Anticipated Strategic Collaborations Designed to Further the Company's Goal of Ensuring Global Supply of a Safe and Effective Vaccine for COVID-19
Emergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner for Johnson & Johnson’s Lead Vaccine Candidate for COVID-19
Emergent BioSolutions Inc. (NYSE:EBS) today announced an agreement whereby Emergent will deploy its contract development and manufacturing (CDMO) services to support the manufacturing of Johnson & Johnson’s lead vaccine candidate for COVID-19 that leverages the AdVac® and PER.C6® technologies from the Janssen Pharmaceutical Companies of Johnson & Johnson.
Emergent BioSolutions Inc. announced the appointment of Dr. Karen L. Smith, M.D., Ph.D. as chief medical officer with responsibility for leading and further establishing Emergent’s global integrated capability in clinical development, medical affairs, and regulatory affairs.
Emergent BioSolutions to Release First Quarter 2020 Financial Results and Conduct Conference Call on April 30, 2020
Emergent BioSolutions Inc. will host a conference call on Thursday, April 30, 2020 at 5:00 pm to discuss the financial results for the first quarter of 2020, recent business developments, revenue guidance for the second quarter of 2020, and financial outlook for full year 2020..
Biopharma companies are attacking the COVID-19 pandemic from many fronts. Emergent BioSolutions is among those leading the fight.
Emergent BioSolutions Inc. (NYSE: EBS) today announced the appointment of Nina DeLorenzo to the position of senior vice president for global public affairs.
Emergent BioSolutions Partners with U.S. Government for Comprehensive Response to Expedite Development of Plasma-Derived Therapy for COVID-19
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has entered into a formal partnership with the U.S. government to expedite development of a plasma-derived therapy for patients with coronavirus disease 2019 (COVID-19).
Emergent BioSolutions Inc. announced an agreement with Novavax, Inc. whereby Emergent will provide molecule-to-market contract development and manufacturing services to produce Novavax’s NanoFlu™, its recombinant quadrivalent seasonal influenza vaccine candidate with its proprietary Matrix-M™ adjuvant.
Vaxart Announces It Entered Into An Agreement With Emergent Biosolutions For The Development And Manufacturing Of Oral Coronavirus (Covid-19) Vaccine Candidate
Oral Vaccines based on Proprietary VAAST™ Platform Offer Potential Key Advantages in Global Quest to Develop Coronavirus Vaccine
Emergent Biosolutions Signs Development And Manufacturing Agreement With Vaxart For Their Experimental Oral Vaccine Candidate For Coronavirus Disease
Emergent BioSolutions Inc. announced that it has entered into an agreement with Vaxart, Inc., a clinical-stage biotechnology company, whereby Emergent has agreed to utilize its molecule-to-market contract development and manufacturing services to develop and manufacture Vaxart’s experimental oral vaccine candidate for coronavirus disease.
Emergent BioSolutions Initiates Development of Plasma-Derived Product Candidates for the Treatment and Prevention of Coronavirus Disease
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has initiated development of two product candidates for the treatment and prevention of coronavirus disease (COVID-19).
Emergent BioSolutions Signs Development and Manufacturing Agreement With Novavax for Experimental Vaccine Candidate for Coronavirus Disease
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has entered into an agreement with Novavax, Inc. (NASDAQ:NVAX) whereby Emergent will collaborate with Novavax, utilizing its molecule-to-market contract development and manufacturing (CDMO) services to support bringing into the clinic Novavax’s novel experimental vaccine candidate to protect against coronavirus disease (COVID-19).